Content about Alli

March 26, 2014

GlaxoSmithKline began alerting consumers that some bottles of its Alli over-the-counter weight-loss medication have been tampered with.

MOON TOWNSHIP, Pa. — GlaxoSmithKline on Wednesday began alerting consumers that some bottles of its Alli over-the-counter weight-loss medication have been tampered with. "Consumer safety is GSK's primary concern," the company stated. "We have initiated an investigation and are working with the Food and Drug Administration."

The outer carton of any tampered product may look authentic, but there are several tell-tale signs that the product has been tampered with, GSK cautioned, including:  

January 9, 2014

GlaxoSmithKline is offering a new online campaign under the Alli brand to support healthy weight-loss resolutions, the company said Thursday.

PARSIPPANY, N.J. — GlaxoSmithKline is offering a new online campaign under the Alli brand to support healthy weight-loss resolutions, the company said Thursday.

January 15, 2013

GlaxoSmithKline’s Alli is back. And while the brand is still slightly down versus year-ago sales — Alli posted a sales decline of 8.9% to $13.9 million across all channels for the 12 weeks ended Nov. 4, according to SymphonyIRI Group — overall, the category is trending up 15% in quarterly sales increases.

GlaxoSmithKline’s Alli is back. And while the brand is still slightly down versus year-ago sales  — Alli posted a sales decline of 8.9% to $13.9 million across all channels for the 12 weeks ended Nov. 4, according to SymphonyIRI Group — overall, the category is trending up 15% in quarterly sales increases. The recent resumption of marketing efforts behind Alli coupled with recent New Year’s resolutions should maintain Alli’s position as the top-selling diet-aid tablet, and the only OTC option in the category.

December 13, 2012

GlaxoSmithKline Consumer Healthcare and TV personality Samantha Harris have teamed up to announce the launch of "Let's Fight Holiday Fat" — a new, free online guide that provides weight maintenance support for Americans trying to squeeze in healthy eating and exercise this season.

PARSIPPANY, N.J. — GlaxoSmithKline Consumer Healthcare and TV personality Samantha Harris have teamed up to announce the launch of "Let's Fight Holiday Fat" — a new, free online guide that provides weight maintenance support for Americans trying to squeeze in healthy eating and exercise this season.

The tool, created courtesy of Alli, an FDA-approved weight-loss aid available without a prescription — is for anyone interested in overcoming the holidays and being weight-loss-ready for 2013.

November 5, 2012

The opportunity for weight loss certainly hasn’t gone away — sales of diet-aid liquids were up 12.8% to $1.2 billion for the 52 weeks ended Sept. 9 across food, drug and mass (excluding Walmart), according to SymphonyIRI.

The opportunity for weight loss certainly hasn’t gone away — sales of diet-aid liquids were up 12.8% to $1.2 billion for the 52 weeks ended Sept. 9 across food, drug and mass (excluding Walmart), according to SymphonyIRI. And due to the temporary absence of GlaxoSmithKline’s Alli — unavailable because of a raw-ingredient sourcing issue — sales of diet-aid tablets are down with a 7% decline to a dollar base of 
$205.4 million. 
Alli had been removed from the market in March due to the third-party supply issue and returned in late June. 


September 24, 2012

Alli, pictured here at a CVS, is back on shelf.

LEBANON, Pa. — Alli, pictured here at a CVS, is back on shelf. Supply issues earlier this year took many facings of GlaxoSmithKline's Alli nonprescription weight loss solution out of play, but no longer, as of earlier this summer. With Alli's absence, the hefty weight-loss solution fell behind Hydroxycut Advanced in number of units sold but still led all diet aids in sales with an 18.2% dollar share (to Hydroxycut Advanced's 9.6%).

July 9, 2012

GlaxoSmithKline on Monday issued an email blast to registrants of its MyAlli.com site that Alli will be making its way back to store shelves later this month.

PITTSBURGH — GlaxoSmithKline on Monday issued an email blast to registrants of its MyAlli.com site that Alli will be making its way back to store shelves later this month.

September 12, 2011


As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 



As the clock winds down on the patent exclusivity of the industry’s biggest blockbuster drug in November, speculation continues to grow that Pfizer will look to flip the switch on an OTC version of Lipitor (atorvastatin) before generic competition whittles away at the $7 billion behemoth. 


July 28, 2011

GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

PHILADELPHIA — GlaxoSmithKline expects to close the deal on the divestiture of several over-the-counter brands that were identified in April, the company stated Tuesday as part of its second-quarter earnings results.

"The divestment of noncore OTC assets in the [United States] and Europe will further aid our strategy to accelerate growth and increase the focus of our Consumer Healthcare business," GSK stated. "We are making progress to divest these products by late 2011, subject to realizing appropriate value for shareholders."

February 7, 2011

GlaxoSmithKline has received a license extension in Europe for its popular weight-loss pill Alli.

LONDON — GlaxoSmithKline has received a license extension in Europe for its popular weight-loss pill Alli.

The drug maker said it plans to sell new chewable tablets this spring, available at pharmacies throughout the United Kingdom.

Alli has been available in the United Kingdom since early 2009.

May 31, 2010

GlaxoSmithKline Consumer Healthcare last week announced it will update the Alli product label to alert...

August 23, 2009

This agency pulls no punches. The merest blip of a post-marketing serious adverse event report,...

NEW YORK This agency pulls no punches. The merest blip of a post-marketing serious adverse event report, and the agency is acting sooner than later. Because when you get right down to it, out of all the prescriptions for Xenical (approved for sale April 1999), out of all the people who have tried Alli when the ingredient orlistat was switched over the counter (in February 2007), there have been as many adverse events reported in the United States around orlistat and liver injury as there have been Boston Red Sox championships in the past 70 years: two.